Proarrhythmia as a pharmacogenomic entity: A critical review and formulation of a unifying hypothesis
Author:
Open Access
- 15 August 2005
- journal article
- review article
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 67 (3) , 419-425
Abstract
Proarrhythmia represents an extreme example of the phenomenon that drug effects vary widely among individuals. Studies of mechanisms leading to proarKeywords
This publication has 34 references indexed in Scilit:
- Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: Some answers but still questions*1Clinical Pharmacology & Therapeutics, 2004
- Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1 , and KCNE2 in drug-induced long QT syndrome patientsJournal of Molecular Medicine, 2004
- Cloning and initial characterization of the human cardiac sodium channel (SCN5A) promoter.Cardiovascular Research, 2004
- Assessing predictors of drug-induced torsade de pointesTrends in Pharmacological Sciences, 2003
- Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expressionNature Genetics, 2001
- Intravenous therapy for atrial fibrillation: More choices, more questions, more trialsAmerican Heart Journal, 1999
- MiRP1 Forms IKr Potassium Channels with HERG and Is Associated with Cardiac ArrhythmiaCell, 1999
- Thioridazine Lengthens Repolarization of Cardiac Ventricular Myocytes by Blocking the Delayed Rectifier Potassium CurrentThe Journal of Pharmacology and Experimental Therapeutics, 1999
- Mechanism of the Cardiotoxic Actions of TerfenadineJAMA, 1993
- Clinical and electrophysiologic assessment of oral flecainide acetate for recurrent ventricular tachycardia: Evidence for exacerbation of electrical instabilityThe American Journal of Cardiology, 1983